Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Comment by Smokey1958on Apr 21, 2021 11:08am
105 Views
Post# 33036935

RE:RE:GOOD READ!

RE:RE:GOOD READ!

The following title for this study represents even more support for the game changing potential of AcuVid, particularly for the niche it could occupy ...which is expansive.

https://www.nature.com/articles/s41598-021-82787-z
 

"Saliva is more sensitive than nasopharyngeal or nasal swabs for diagnosis of asymptomatic and mild COVID-19 infection"


Smokey1958 wrote:

To add to the reading list, thanks Freedom! This study was carried out in January of 2021 and published in the The American Journal of Cardiology. I will include the link for the study that reviewed previous analysis of over 7000 samples.

Their conclusion ....

Sample collection through saliva or nasopharyngeal swabbing does not differ significantly in sensitivity. Salivary collection, however, is much less costly.

https://www.acc.org/latest-in-cardiology/journal-scans/2021/01/18/22/48/the-sensitivity-and-costs-of-testing

FREEDOM55 wrote: https://www.the-scientist.com/news-opinion/covid-19-diagnostics-how-do-saliva-tests-compare-to-swabs--68035

 

 



<< Previous
Bullboard Posts
Next >>